CDNA – CareDx, Inc
CDNA — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
13.23
Margin Of Safety %
-45
Put/Call OI Ratio
4.54
EPS Next Q Diff
-0.12
EPS Last/This Y
1.58
EPS This/Next Y
0.16
Price
46.7
Target Price
52.33
Analyst Recom
1.86
Performance Q
Upside
55.2%
Beta
2.41
Ticker: CDNA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | CDNA | 28.77 | 0.79 | 1.00 | 1296 |
| 2026-07-14 | CDNA | 28.92 | 0.78 | 0.36 | 1308 |
| 2026-07-15 | CDNA | 29.73 | 0.79 | 0.00 | 1314 |
| 2026-07-16 | CDNA | 40.32 | 0.79 | 4.50 | 1315 |
| 2026-07-17 | CDNA | 39.73 | 3.15 | 12.09 | 4814 |
| 2026-07-20 | CDNA | 38.36 | 4.05 | 1.63 | 5118 |
| 2026-07-21 | CDNA | 38.54 | 4.02 | 0.11 | 5118 |
| 2026-07-22 | CDNA | 37.8 | 3.98 | 5.00 | 5127 |
| 2026-07-23 | CDNA | 37.64 | 3.98 | 0.44 | 5128 |
| 2026-07-24 | CDNA | 37.15 | 3.97 | 1.45 | 5133 |
| 2026-07-27 | CDNA | 36.56 | 3.96 | 999.99 | 5147 |
| 2026-07-28 | CDNA | 35.77 | 3.96 | 0.10 | 5146 |
| 2026-07-29 | CDNA | 35.41 | 3.91 | 0.11 | 5159 |
| 2026-07-30 | CDNA | 39.85 | 3.91 | 0.37 | 5161 |
| 2026-07-31 | CDNA | 43.7 | 3.72 | 0.95 | 5219 |
| 2026-08-03 | CDNA | 47.67 | 4.88 | 2.18 | 8208 |
| 2026-08-04 | CDNA | 47.12 | 4.53 | 1.60 | 9901 |
| 2026-08-05 | CDNA | 45.52 | 4.52 | 0.77 | 9895 |
| 2026-08-06 | CDNA | 44.77 | 4.66 | 0.51 | 9844 |
| 2026-08-07 | CDNA | 46.66 | 4.54 | 1.66 | 9897 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | CDNA | 28.76 | 132.0 | - | 0.93 |
| 2026-07-14 | CDNA | 28.94 | 132.0 | - | 0.93 |
| 2026-07-15 | CDNA | 29.75 | 132.0 | - | 0.93 |
| 2026-07-16 | CDNA | 40.33 | 132.0 | - | 0.93 |
| 2026-07-17 | CDNA | 39.69 | 132.0 | - | 0.93 |
| 2026-07-20 | CDNA | 38.39 | 132.0 | - | 0.93 |
| 2026-07-21 | CDNA | 38.54 | 132.0 | - | 0.93 |
| 2026-07-22 | CDNA | 37.78 | 132.0 | - | 0.93 |
| 2026-07-23 | CDNA | 37.65 | 132.0 | - | 0.93 |
| 2026-07-24 | CDNA | 37.14 | 132.0 | - | 0.93 |
| 2026-07-27 | CDNA | 36.34 | 132.0 | - | 0.93 |
| 2026-07-28 | CDNA | 35.77 | 132.0 | - | 0.93 |
| 2026-07-29 | CDNA | 35.40 | 132.0 | - | 0.93 |
| 2026-07-30 | CDNA | 38.08 | 132.0 | - | 0.93 |
| 2026-07-31 | CDNA | 43.64 | 132.0 | - | 0.93 |
| 2026-08-03 | CDNA | 47.87 | 132.0 | - | 0.93 |
| 2026-08-04 | CDNA | 47.87 | 132.0 | - | 0.93 |
| 2026-08-05 | CDNA | 45.53 | -17.9 | - | 1.16 |
| 2026-08-06 | CDNA | 44.78 | -17.9 | - | 1.16 |
| 2026-08-07 | CDNA | 46.70 | -15.7 | - | 1.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | CDNA | -3.02 | -0.49 | 17.85 |
| 2026-07-14 | CDNA | -3.01 | -0.49 | 17.85 |
| 2026-07-15 | CDNA | -3.01 | -0.49 | 17.85 |
| 2026-07-16 | CDNA | -3.01 | -0.49 | 17.85 |
| 2026-07-17 | CDNA | -3.01 | -0.49 | 17.85 |
| 2026-07-20 | CDNA | -5.72 | -0.53 | 17.85 |
| 2026-07-21 | CDNA | -5.53 | -0.53 | 17.85 |
| 2026-07-22 | CDNA | -5.53 | -0.53 | 17.85 |
| 2026-07-23 | CDNA | -5.53 | -0.53 | 17.85 |
| 2026-07-24 | CDNA | -5.18 | -0.53 | 17.85 |
| 2026-07-27 | CDNA | -5.18 | -2.43 | 13.25 |
| 2026-07-28 | CDNA | -5.18 | -2.43 | 13.25 |
| 2026-07-29 | CDNA | -5.18 | -2.43 | 13.25 |
| 2026-07-30 | CDNA | -5.18 | -2.43 | 13.25 |
| 2026-07-31 | CDNA | -5.18 | -2.43 | 13.25 |
| 2026-08-03 | CDNA | -5.18 | -1.52 | 13.23 |
| 2026-08-04 | CDNA | -5.18 | -1.52 | 13.23 |
| 2026-08-06 | CDNA | -6.58 | -1.52 | 13.23 |
| 2026-08-07 | CDNA | -6.58 | -1.52 | 13.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.37
Avg. EPS Est. Current Quarter
0.24
Avg. EPS Est. Next Quarter
0.25
Insider Transactions
-6.58
Institutional Transactions
-1.52
Beta
2.41
Average Sales Estimate Current Quarter
120
Average Sales Estimate Next Quarter
121
Fair Value
25.83
Quality Score
87
Growth Score
54
Sentiment Score
99
Actual DrawDown %
43.1
Max Drawdown 5-Year %
-94
Target Price
52.33
P/E
22.51
Forward P/E
34.46
PEG
0.7
P/S
5.27
P/B
5.65
P/Free Cash Flow
28.52
EPS
2.07
Average EPS Est. Cur. Y
1.18
EPS Next Y. (Est.)
1.33
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
24.23
Relative Volume
0.97
Return on Equity vs Sector %
-1.2
Return on Equity vs Industry %
14.6
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.24
EBIT Estimation
◆
CDNA
Healthcare
$46.69
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
73.1
Range 1M
84.8%
Sup Dist
5.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
109.2%
52W%
91.1%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-11.1% upside
Upside
-11.1%
Quality
87
MoS
-45%
CDNA — P/E HistoricalDiagnostics & Research
CareDx, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 761
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
CDNA
Latest News
—
Caricamento notizie per CDNA…
stock quote shares CDNA – CareDx, Inc Stock Price stock today
news today CDNA – CareDx, Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch CDNA – CareDx, Inc yahoo finance google finance
stock history CDNA – CareDx, Inc invest stock market
stock prices CDNA premarket after hours
ticker CDNA fair value insiders trading